Nitric oxide inhalation - GeNO

Drug Profile

Nitric oxide inhalation - GeNO

Alternative Names: GeNOsyl; MVG-2000

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator GeNO LLC
  • Class Antiacnes; Antiandrogens; Antibacterials; Antifungals; Antihypertensives; Antivirals; Free radicals; Macromolecular substances; Nitrogen oxides; Non-opioid analgesics; Small molecules; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoxic respiratory failure
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pulmonary arterial hypertension
  • No development reported Hypoxic respiratory failure

Most Recent Events

  • 01 Sep 2016 Geno completes the phase II PHiano trial in Pulmonary arterial hypertension in USA (NCT01265888)
  • 15 Mar 2016 Biomarkers information updated
  • 12 Feb 2016 No development reported - Preregistration for Hypoxic respiratory failure (In neonates) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top